FMD vs. pharmacological approaches for endothelial function.
Tanaka
Hirofumi
H
Department of Kinesiology, University of Wisconsin-Madision, USA, tanaka1@wisc.edu
D000109:Acetylcholine / Q000494:pharmacology*; D001916:Brachial Artery / Q000187:drug effects* / Q000502:physiology*; D004730:Endothelium, Vascular / Q000502:physiology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D009569:Nitric Oxide / Q000502:physiology; D010827:Physiology / Q000379:methods; D012039:Regional Blood Flow / Q000502:physiology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology*; D014665:Vasodilator Agents / Q000494:pharmacology*; D019323:omega-N-Methylarginine / Q000494:pharmacology
D004791:Enzyme Inhibitors; D014665:Vasodilator Agents; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D000109:Acetylcholine